We also showed that patients with a complete response to anti-PD-1 immunotherapy had high levels of CD137+ cells in the tumour microenvironment within tertiary lymphoid structures surrounding the tumour mass [20]. This evidence concerns the gene TNFRSF9 and neoplasm.